Class summary at a glance.

Every drug in the Histamine-1 Receptor Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 10tracked in Part D
CY24 Part D spend: $214.1Mcombined across class
Total Rx claims: 9.1M3.9M unique beneficiaries
Generic mfrs (active): 53across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Azelastine

Brand: Azelastine Hydrochloride · 5.1M Part D claims (CY24) · 2.4M beneficiaries · First FDA approval: 2009-12-01

10 generic mfrs 0 plans require PA

Low NADAC$0.286

→

Avg plan cost$0.552

Part D spend $131.8M 2× spread, current vs floor

Class share

62%

of class CY24 spend

View profile →

Levocetirizine Dihydrochloride

Brand: Xyzal · 3.6M Part D claims (CY24) · 1.3M beneficiaries · First FDA approval: 2011-02-24

11 generic mfrs 0 plans require PA

Low NADAC$0.055

→

Avg plan cost$0.104

Part D spend $44.1M 2× spread, current vs floor

Class share

21%

of class CY24 spend

View profile →

Bepotastine Besilate

Brand: Bepreve · 101K Part D claims (CY24) · 32K beneficiaries · First FDA approval: 2009-09-08

4 generic mfrs 0 plans require PA

Low NADAC$13.03

→

Avg plan cost$17.35

Part D spend $16.6M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Desloratadine

Brand: Clarinex · 238K Part D claims (CY24) · 91K beneficiaries · First FDA approval: 2013-01-11

6 generic mfrs 0 plans require PA

Low NADAC$0.287

→

Avg plan cost$2.22

Part D spend $10.5M 8× spread, current vs floor

Class share

of class CY24 spend

View profile →

Cetirizine

Brand: Cetirizine Hydrochloride · 35K Part D claims (CY24) · 14K beneficiaries · First FDA approval: 2008-07-24

9 generic mfrs 0 plans require PA

Low NADAC$0.021

→

Avg plan cost$0.819

Part D spend $5.5M 39× spread, current vs floor

Class share

of class CY24 spend

View profile →

Carbinoxamine

Brand: CARBZAH · 9K Part D claims (CY24) · 4K beneficiaries · First FDA approval: 2011-05-27

4 generic mfrs 32 plans require PA

Low NADAC$0.432

→

Avg plan cost$0.814

Part D spend $3.6M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Diphenhydramine

Brand: Banophen · 95K Part D claims (CY24) · 39K beneficiaries · First FDA approval: 1972-11-27

8 generic mfrs

Low NADAC$0.944

→

Avg plan cost$0.961

Part D spend $2.0M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Alcaftadine

Brand: LASTACAFT · — Part D claims (CY24) · First FDA approval: 2010-11-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Azelastine and Fluticasone

Brand: DYMISTA · — Part D claims (CY24) · First FDA approval: 2016-10-01

Brand-only (no generics) 0 plans require PA Discontinued

Low NADAC$2.26

→

Avg plan cost$3.98

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Desloratadine and Pseudoephedrine

Brand: CLARINEX-D 12 HOUR · — Part D claims (CY24) · First FDA approval: 2021-06-01

1 generic mfrs 0 plans require PA

Low NADAC$6.06

→

Avg plan cost$6.06

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.